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EPH-­‐B4	  ACTIVATION	  REDUCES	  NEOINTIMAL	  HYPERPLASIA	  IN	  HUMAN	  
SAPHENOUS	  VEIN.	  Daniel	  J	  Wong,	  Alan	  Dardik.	  Department	  of	  Surgery	  and	  
Department	  of	  Vascular	  Biology	  and	  Therapeutics,	  Yale	  University,	  School	  of	  
Medicine,	  New	  Haven,	  CT.	  	  
	  
Despite	  the	  rise	  in	  percutaneous	  interventions,	  bypass	  surgery	  is	  an	  essential	  
therapy	  for	  patients	  with	  advanced	  coronary	  and	  peripheral	  artery	  disease.	  Nearly	  
half	  of	  the	  saphenous	  vein	  grafts	  used	  in	  these	  operations	  are	  eventually	  
complicated	  by	  pathologic	  remodeling	  known	  as	  neointimal	  hyperplasia	  (NIH).	  
Recent	  work	  in	  animal	  models	  has	  shown	  that	  the	  development	  of	  NIH	  can	  be	  
reduced	  by	  stimulation	  of	  the	  receptor	  tryrosine	  kinase	  Eph-­‐B4	  by	  systemic	  
injections	  of	  its	  ligand	  ephrin-­‐b2.	  The	  purpose	  of	  this	  study	  was	  to	  determine	  
whether	  the	  reduction	  of	  intimal	  hyperplasia	  observed	  with	  Eph-­‐B4	  stimulation	  in	  
animal	  models	  translated	  into	  human	  tissues.	  Specifically	  we	  sought	  to	  determine	  
whether	  the	  development	  of	  intimal	  hyperplasia	  in	  human	  saphenous	  vein	  (HSV)	  
tissue	  could	  be	  reduced	  with	  ephrin-­‐b2/fc	  treatments.	  We	  also	  investigated	  whether	  
Eph-­‐B4	  stimulation	  in	  human	  endothelial	  cells	  caused	  similar	  downstream	  signaling	  
changes	  observed	  in	  animal	  cells.	  Finally	  we	  wanted	  to	  assess	  endothelial	  Eph-­‐B4	  
stimulation	  was	  achievable	  with	  adventitial	  delivery	  of	  ephrin-­‐B2/fc.	  Excess	  
saphenous	  vein	  from	  patients	  undergoing	  coronary	  artery	  bypass	  surgery	  was	  taken	  
from	  the	  OR	  and	  put	  in	  organ	  culture	  for	  14	  days	  with	  or	  without	  treatment	  with	  
ephrin-­‐b2/fc.	  At	  the	  end	  of	  14	  days	  histologic	  measurements	  of	  the	  intima:media	  
(I:M)	  were	  used	  to	  track	  the	  development	  of	  (NIH).	  The	  mean	  baseline	  I:M	  ratio	  was	  
0.456	  ±	  0.097	  (n=19).	  Over	  14	  days	  in	  organ	  culture	  this	  ratio	  increased	  to	  0.726	  ±	  
0.142	  (n=19)	  in	  untreated	  veins	  and	  0.630	  ±	  0.132	  (n=19)	  in	  treated	  veins	  which	  
was	  significantly	  different	  (p=.017).	  Using	  quantitative	  reverse	  transcription	  
polymerase	  chain	  reaction	  (qPCR)	  analysis	  gene	  expression	  changes	  in	  organ	  
culture	  were	  measured.	  Eph-­‐B4	  and	  ephrin-­‐b2	  decreased	  while	  osteopontin	  
expression	  increased	  in	  both	  treated	  and	  untreated	  groups.	  Using	  a	  human	  
endothelial	  cell	  line,	  we	  observed	  increases	  in	  phosphorylated	  AKT	  and	  caveolin-­‐1	  
with	  ephrin-­‐b2/fc	  treatment.	  Finally	  using	  an	  arterial	  flow	  model	  bio-­‐reactor	  we	  
demonstrated	  that	  endothelial	  eph-­‐B4	  phosphorylation	  was	  achievable	  with	  
adventitial	  application	  of	  ephrin-­‐B2/fc	  in	  a	  pluronic	  hydrogel	  after	  24	  hours	  in	  
arterial	  flow.	  In	  conclusion	  we	  show	  that	  Eph-­‐B4	  stimulation	  reduces	  the	  NIH	  
development	  in	  vitro	  in	  HSV	  organ	  culture.	  Eph-­‐B4	  stimulation	  activates	  similar	  
signaling	  cascades	  in	  human	  endothelial	  cells	  as	  in	  mice.	  Finally	  that	  local	  delivery	  of	  
eprhin-­‐b2/fc	  is	  possible	  through	  a	  pluronic	  hydrogel	  applied	  to	  the	  adventitia	  of	  a	  
vein.	  Combined	  these	  results	  continue	  to	  point	  to	  Eph-­‐B4	  stimulation	  as	  a	  promising	  
target	  for	  a	  therapy	  to	  reduce	  NIH	  in	  bypass	  recipients,	  however,	  longer	  term	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Introduction:	  	  
Bypass	  Surgery	  and	  Graft	  Failure	  	  
	   In	  1906	  Dr.	  Jose	  Goyanes	  of	  Spain	  performed	  the	  first	  successful	  vein	  graft	  in	  
humans.	  He	  used	  a	  section	  of	  popliteal	  vein	  as	  an	  interposition	  graft	  in	  the	  popliteal	  
artery	  following	  a	  syphilitic	  aneurysm	  resection	  (1,	  2).	  	  Since	  then	  surgeons	  have	  
employed	  autogenous	  vein	  to	  bypass	  arterial	  circulation	  for	  over	  100	  years.	  Dr.	  
René	  Favaloro	  of	  Argentina	  was	  the	  first	  surgeon	  to	  use	  a	  vein	  graft	  to	  bypass	  a	  
coronary	  artery	  in	  1967	  (3).	  Today	  cardiovascular	  disease	  is	  the	  leading	  cause	  of	  
death	  in	  the	  United	  States	  (4).	  Peripheral	  artery	  disease	  (PAD)	  is	  also	  a	  major	  source	  
of	  morbidity	  and	  mortality	  with	  an	  estimated	  prevalence	  of	  9-­‐12	  million	  Americans	  
which	  is	  sure	  to	  grow	  with	  the	  increasing	  age	  and	  prevalence	  of	  diabetes	  in	  our	  
patient	  population	  (5).	  Despite	  the	  meteoric	  increase	  in	  endovascular	  interventions,	  
as	  much	  as	  300%	  over	  the	  last	  decade	  in	  some	  academic	  training	  programs,	  bypass	  
surgery	  remains	  an	  important	  therapy	  in	  treating	  advanced	  coronary	  and	  peripheral	  
artery	  disease	  (6,	  7).	  Approximately	  250,000	  coronary	  artery	  bypass	  graft	  (CABG)	  
procedures	  and	  80,000	  lower	  extremity	  bypass	  surgeries	  are	  performed	  per	  year	  in	  
the	  United	  States	  (8).	  	  
	   Within	  bypass	  surgery,	  saphenous	  vein	  remains	  the	  most	  commonly	  used	  
and	  durable	  conduit	  for	  arterial	  reconstruction.	  Despite	  this	  a	  significant	  portion	  of	  
saphenous	  vein	  grafts	  are	  eventually	  complicated	  by	  excessive	  venous	  remodeling	  
resulting	  in	  graft	  thrombosis,	  failure	  and	  the	  associated	  patient	  morbidity	  and	  
mortality.	  Approximately	  20%	  of	  coronary	  artery	  bypass	  are	  no	  longer	  patent	  at	  1	  
year	  and	  this	  number	  increases	  to	  40%	  at	  5	  years	  (9).	  In	  the	  peripheral	  arterial	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system	  patency	  of	  the	  graft	  can	  vary	  depending	  on	  the	  location	  of	  the	  distal	  
anastomoses	  as	  well	  as	  the	  indication	  for	  the	  bypass	  such	  as	  claudication	  versus	  
critical	  limb	  ischemia.	  In	  a	  recent	  large	  study	  1	  year	  overall	  patency	  rates	  for	  
bypasses	  for	  critical	  limb	  ischemia	  was	  61%(10).	  5	  year	  patency	  of	  grafts	  employed	  
for	  claudication	  had	  variable	  5	  year	  patency	  rates	  ranging	  from	  48-­‐81%	  depending	  
on	  the	  anatomic	  level	  of	  distal	  anastomoses	  (11,	  12).	  	  
	   It	  has	  long	  been	  known	  that	  autogenous	  vein	  graft	  patency	  exceeds	  that	  of	  
artificial	  conduits	  such	  as	  polytetrafluoroethylene	  (PTFE)(13).	  However	  we	  have	  
also	  observed	  that	  that	  internal	  mammary	  artery	  grafts	  employed	  in	  CABGs	  exhibit	  
better	  long	  term	  patency	  than	  saphenous	  vein	  grafts.	  (14)	  This	  variation	  in	  patency	  
rates	  both	  in	  respect	  to	  location,	  host	  status,	  and	  material	  underline	  the	  dynamic	  
nature	  of	  the	  biologic	  processes	  that	  vein	  grafts	  undergo	  in	  the	  arterial	  system.	  
Thus,	  understanding	  the	  molecular	  mechanisms	  involved	  in	  long	  term	  graft	  patency	  
as	  well	  as	  possible	  pathways	  for	  improving	  patency	  rates	  will	  remain	  an	  important	  
goal	  of	  research.	  
	  
Vein	  Graft	  Adaptation	  and	  Neointimal	  Hyperplasia	  	  	  
	   Under	  normal	  physiologic	  conditions	  the	  vein	  is	  a	  thin	  walled,	  highly	  
compliant,	  vessel.	  The	  vein	  undergoes	  lower	  pressures,	  shear	  stress,	  oxygenation,	  
and	  flow	  than	  the	  artery.	  	  Both	  the	  arterial	  and	  venous	  vessel	  wall	  are	  composed	  of	  
three	  layers:	  the	  intima,	  media,	  and	  adventitia.	  The	  media	  of	  the	  vein	  is	  composed	  of	  
a	  thin	  layer	  of	  vascular	  smooth	  muscle	  whereas	  the	  arteries	  possess	  a	  much	  thicker	  
media	  and	  adventitia.	  Veins	  also	  contain	  less	  elastic	  tissue	  than	  arteries.	  One	  final	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important	  difference	  between	  the	  vein	  and	  the	  artery	  is	  that	  the	  vein	  has	  
intraluminal	  valves	  to	  prevent	  the	  reverse	  flow	  of	  blood.	  Overall,	  the	  thinner	  vessel	  
wall	  of	  the	  vein	  wall	  allows	  for	  a	  more	  compliant	  vessel	  that	  adapts	  to	  physiologic	  
fluctuations	  in	  volume	  load	  and	  pressure	  while	  returning	  blood	  to	  the	  heart.	  
However,	  this	  thin	  walled	  venous	  architecture	  is	  disrupted	  when	  the	  vein	  is	  taken	  
from	  the	  low	  flow,	  low	  pressure,	  low	  shear	  stress	  venous	  circulation	  and	  place	  into	  
the	  high	  flow,	  high	  pressure,	  high	  shear	  stress	  arterial	  circulation	  during	  bypass	  
surgery.	  	  
	   Since	  the	  1950s	  investigators	  have	  noted	  both	  the	  gross	  and	  histologic	  
changes	  that	  veins	  undergo	  following	  anastomosis	  into	  the	  arterial	  circulation.	  	  
Barker	  et	  al.,	  first	  referred	  to	  these	  changes	  as	  ‘arterialization’	  and	  since	  then	  
numerous	  groups	  have	  detailed	  the	  changes	  in	  the	  vessel	  wall	  of	  the	  vein	  graft	  (15,	  
16).	  These	  changes	  include	  an	  increase	  in	  overall	  diameter	  accompanied	  by	  a	  
thickening	  in	  width	  of	  all	  three	  layers	  of	  the	  vessel	  wall:	  intima,	  media,	  and	  
adventitia	  (Figure	  1).	  The	  intima	  undergoes	  the	  most	  drastic	  changes.	  In	  the	  normal	  
vein	  the	  intima	  is	  a	  single	  layer	  of	  squamous	  epithelium.	  Following	  implantation	  
into	  the	  arterial	  system,	  the	  intima	  of	  the	  vein	  graft	  is	  invaded	  by	  smooth	  muscle	  
cells	  which	  proliferate	  and	  deposit	  extracellular	  matrix	  (17).	  This	  thickening	  of	  the	  
intima	  has	  been	  described	  histologically	  as	  ‘fibrous	  proliferation’,	  ‘fibrocellular	  
thickening’	  or	  grossly	  as	  a	  ‘firm	  intramural	  nodule	  of	  white,	  fibrous	  tissue…covered	  
by	  smooth	  tan	  endothelium’(18-­‐20).	  We	  now	  term	  this	  pathologic	  thickening	  as	  
‘neointimal	  hyperplasia’.	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Figure	  1.	  H&E	  histology	  of	  normal	  saphenous	  vein	  (a)	  and	  patent	  vein	  graft	  (b).	  
Image	  taken	  from	  Kudo	  et	  al.,	  2007(21)	  
	  
	   The	  complex	  set	  of	  structural	  and	  molecular	  changes	  that	  the	  vein	  graft	  
undergoes	  when	  placed	  in	  arterial	  circulation	  are	  a	  necessary	  adaption	  to	  the	  
demands	  of	  the	  arterial	  environment.	  This	  adaptive	  process	  is	  referred	  to	  as	  vein	  
graft	  adaptation.	  Neointimal	  hyperplasia	  refers	  to	  the	  excessive	  remodeling	  which	  
leads	  to	  stenosis	  and	  compromise	  of	  graft	  patency.	  In	  a	  2005	  review	  Mitra	  et	  al	  
offered	  a	  useful	  chronologic	  framework	  to	  view	  both	  the	  stimuli	  and	  molecular	  
mechanisms	  for	  the	  changes	  to	  the	  vessel	  wall	  (17).	  These	  steps	  are:	  initial	  
endothelial	  cell	  damage,	  platelet	  activation,	  leukocyte	  recruitment	  and	  subsequent	  
inflammation,	  activation	  of	  the	  coagulation	  cascade,	  and	  smooth	  muscle	  cell	  
migration	  and	  proliferation.	  	  
	   Harvesting	  of	  the	  saphenous	  vein	  in	  bypass	  surgery	  is	  a	  traumatic	  event	  for	  
the	  vein	  that	  directly	  affects	  both	  the	  endothelium	  and	  adventitia	  of	  the	  vein.	  	  While	  
some	  surgeons	  employ	  an	  in	  situ	  technique	  which	  allows	  the	  majority	  of	  the	  vein	  
graft	  to	  remain	  in	  its	  anatomic	  position	  and	  avoids	  disruption	  and	  stripping	  of	  the	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adventitia,	  most	  peripheral	  bypasses	  and	  all	  cardiac	  bypass	  require	  that	  the	  vein	  be	  
removed	  from	  the	  surrounding	  tissue	  and	  the	  side	  branches	  ligated	  prior	  to	  
anastomosis	  into	  the	  arterial	  circulation.	  During	  harvest,	  the	  vein	  not	  only	  
undergoes	  direct	  surgical	  trauma	  but	  is	  also	  separated	  from	  the	  vasa	  vasorum	  
leading	  to	  hypoxia	  and	  release	  of	  inflammatory	  cytokines	  (22).	  While	  the	  saphenous	  
venous	  endothelium	  usually	  experiences	  shear	  stresses	  around	  0-­‐4	  dynes/cm2,	  this	  
number	  immediately	  rises	  to	  25-­‐30	  dynes/cm2	  	  in	  the	  arterial	  circulation	  which	  
generates	  reactive	  oxygen	  species	  (23).	  Trauma,	  hypoxia,	  and	  the	  hydrostatic	  forces	  
combine	  to	  disrupt	  the	  endothelium	  which	  reduces	  its	  ability	  to	  release	  nitric	  oxide	  
and	  regulate	  intimal	  growth	  (24).	  	  
	   Disrupted	  endothelium	  leads	  to	  platelet	  adhesion,	  accumulation,	  and	  
activation	  which	  in	  turns	  causes	  the	  release	  of	  multiple	  bioactive	  substances	  
including	  platelet	  derived	  growth	  factor	  (PDGF)	  and	  thromboxane	  A2	  which	  are	  
smooth	  muscle	  cell	  mitogens	  (25).	  Other	  factors	  are	  released	  including	  TGF-­‐β,	  Il-­‐1,	  
Il-­‐6,	  and	  Il-­‐8	  (26).	  Platelet	  activation	  initiates	  leukocyte	  adherence,	  recruitment,	  and	  
activation	  with	  subsequent	  chronic	  inflammation	  over	  the	  following	  days	  to	  week.	  
Chronic	  inflammation	  has	  long	  been	  associated	  with	  restenosis.	  Thus	  many	  
therapies	  aimed	  at	  inhibiting	  neointimal	  hyperplasia	  have	  focused	  on	  reducing	  
inflammation	  such	  as	  blockade	  of	  the	  MCP-­‐1	  receptor,	  transfection	  of	  the	  anti-­‐
inflammatory	  vaccine	  virus	  protein	  35K,	  flavanoid	  treatment,	  and	  perivascular	  
treatment	  with	  rapamycin	  which	  have	  all	  shown	  to	  reduce	  neointimal	  hyperplasia	  in	  
animal	  models	  as	  reviewed	  in	  Muto	  et	  al	  (26).	  Disruption	  of	  the	  endothelium	  also	  
leads	  to	  exposure	  of	  tissue	  factor	  which	  in	  turns	  activates	  the	  coagulation	  cascade	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leading	  to	  both	  thrombin	  production	  and	  further	  platelet	  release	  of	  PDGF	  which	  are	  
both	  known	  to	  lead	  to	  smooth	  muscle	  cell	  proliferation	  (17).	  	  
	   The	  biology	  behind	  smooth	  muscle	  cell	  migration	  and	  proliferation	  during	  
the	  first	  month	  of	  vein	  graft	  adaptation	  is	  the	  most	  studied	  component	  of	  neointimal	  
hyperplasia	  (17,	  26,	  27).	  Quiescent	  ‘contractile’	  smooth	  muscle	  cells	  in	  the	  media	  
react	  to	  the	  above	  mentioned	  multiple	  stimuli	  of	  vein	  grafting	  and	  migrate	  into	  the	  
intima	  become	  motile	  ‘synthetic’	  smooth	  muscle	  cells.	  Smooth	  muscle	  cell	  
proliferation	  is	  promoted	  by	  the	  growth	  factors	  PDGF,	  insulin	  growth	  factor-­‐1	  (IGF-­‐
1),	  fibroblast	  growth	  factor	  (FGF),	  TGF-­‐β,	  thrombin,	  and	  the	  cytokines	  IL-­‐1,	  and	  IL-­‐6	  
which	  are	  derived	  from	  the	  endothelium,	  immune	  cells,	  platelets,	  and	  smooth	  
muscle	  cells	  themselves	  (28).	  Both	  the	  MAPK	  and	  AKT	  intracellular	  pathways	  have	  
been	  implicated	  in	  promoting	  smooth	  muscle	  cell	  proliferation.	  ERK	  1/2	  MAPK	  
antagonism	  led	  to	  a	  decrease	  in	  medial	  cell	  proliferation	  and	  intimal	  hyperplasia	  in	  a	  
canine	  model	  of	  vein	  grafting	  (29).	  Similarly	  inhibition	  of	  the	  PI3K-­‐Akt/PKB	  
pathway	  via	  PTEN	  overexpression	  reduced	  intimal	  hyperplasia	  and	  smooth	  muscle	  
cell	  proliferation	  in	  a	  separate	  canine	  experiment	  (30).	  Both	  of	  these	  pathways	  are	  
known	  to	  contribute	  to	  cellular	  mitogenic,	  proliferation,	  and	  survival	  pathways	  and	  
thus	  their	  inhibition	  leading	  to	  a	  reduction	  in	  intimal	  hyperplasia	  further	  implicates	  
smooth	  muscle	  cell	  proliferation	  as	  a	  central	  event	  in	  neointima	  formation.	  	  
	   The	  importance	  of	  extracellular	  matrix	  degradation	  and	  deposition	  during	  
vein	  graft	  adaptation	  has	  been	  increasingly	  recognized	  in	  recent	  years.	  	  Early	  in	  the	  
development	  of	  neointimal	  hyperplasia,	  extracellular	  matrix	  deposition	  is	  required	  
for	  smooth	  muscle	  migration	  and	  matrix	  metalloproteinases	  (MMPs)	  inhibition	  has	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been	  shown	  to	  reduce	  neointima	  formation	  (31).	  Similarly	  overexpression	  of	  the	  
tissue	  inhibitor	  of	  metalloproteinase-­‐3	  (TIMP-­‐3)	  reduced	  neointima	  formation	  as	  
well.	  (32)	  	  Extracellular	  matrix	  deposition	  is	  equally	  important	  to	  vein	  graft	  
adaptation.	  Up	  to	  80%	  of	  the	  neointima	  may	  be	  composed	  of	  matrix.	  This	  combined	  
with	  continued	  upregulation	  of	  TGF-­‐β	  for	  1-­‐6	  months	  following	  vein	  graft	  
implantation	  demonstrate	  the	  importance	  of	  matrix	  deposition	  in	  both	  the	  early	  and	  
long	  term	  vein	  graft	  adaptation	  (33).	  	  
	  
The	  PREVENT	  Trials	  
	   Historically	  smooth	  muscle	  cell	  proliferation	  have	  occupied	  a	  central	  role	  in	  
the	  study	  of	  venous	  neointimal	  hyperplasia.	  The	  focus	  on	  smooth	  muscle	  cell	  
proliferation	  likely	  derives	  from	  their	  dominant	  cellular	  contribution	  to	  the	  
neointima	  lesion	  as	  well	  as	  the	  perceived	  similarities	  between	  the	  more	  widely	  
studied	  arterial	  response	  to	  angioplasty	  injury	  and	  venous	  neointima	  formation.	  
Thus	  the	  first	  molecular	  therapy	  directed	  at	  inhibiting	  vein	  graft	  neointimal	  
hyperplasia	  used	  the	  E2F	  transcription	  factor	  decoy,	  edifoligide.	  Edifoligide	  was	  a	  
double-­‐stranded	  deoxynucleotides	  that	  served	  as	  a	  competitive	  inhibitor	  for	  E2F	  
family	  of	  transcription	  factors	  which	  are	  necessary	  for	  smooth	  muscle	  cells	  to	  
progress	  through	  the	  cell	  cycle	  and	  proliferate	  (34).	  The	  drug	  was	  administered	  by	  a	  
one	  time	  delivery	  of	  pressurized	  deoxynucleotide	  containing	  solution	  on	  the	  back	  
table	  of	  the	  operating	  room	  following	  harvest	  of	  the	  saphenous	  vein	  but	  prior	  to	  
implantation	  as	  a	  vein	  graft	  (35).	  Unfortunately	  large	  randomized	  controlled	  trials	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of	  treatment	  with	  the	  E2f	  decoy	  in	  both	  peripheral	  and	  cardiac	  bypass	  grafts	  did	  not	  
improve	  long	  term	  patency	  (35,	  36).	  	  
	  
Eph-­‐B4	  and	  Venous	  Identity:	  A	  Novel	  Target	  for	  Neointima	  Inhibition	  
	   While	  there	  are	  numerous	  possible	  reasons	  that	  the	  PREVENT	  trials	  did	  not	  
succeed,	  the	  Dardik	  lab	  hypothesized	  that	  a	  novel	  target	  derived	  not	  from	  smooth	  
muscle	  biology	  but	  venous	  biology	  may	  yield	  a	  promising	  target	  in	  inhibiting	  
neointimal	  hyperplasia.	  	  In	  recent	  years,	  the	  critical	  role	  of	  Eph	  (erythropoietin	  
producing	  hepatocellular	  carcinoma)	  family	  of	  tyrosine	  kinases	  and	  their	  ligands	  
(Ephrin)	  in	  the	  process	  of	  venous	  arterial	  identity	  during	  development	  has	  emerged	  
(37,	  38).	  	  Operating	  via	  Sonic	  Hedgehog,	  VEGF,	  and	  Delta-­‐Notch	  signaling	  cascade,	  
ephrin-­‐B2	  expression	  is	  an	  embryonic	  determinant	  of	  arterial	  fate	  whereas	  this	  
cascade	  is	  blocked	  in	  by	  the	  COUP-­‐TFII	  transcription	  factor	  in	  venous	  endothelium	  
leading	  to	  Eph-­‐B4	  expression	  (39,	  40).	  While	  both	  Eph-­‐B4	  and	  ephrin-­‐B2	  are	  
expressed	  throughout	  adulthood,	  it	  was	  uncertain	  whether	  they	  remained	  simply	  as	  
markers	  of	  vessel	  identity	  or	  persisted	  as	  plastic	  determinants	  of	  vessel	  fate	  
especially	  during	  venous	  adaptation.	  	  
	   Using	  a	  rat	  model	  of	  vein	  grafting,	  the	  Dardik	  lab	  demonstrated	  that	  Eph-­‐B4	  
expression	  was	  lost	  during	  vein	  graft	  adaptation	  corresponding	  to	  a	  loss	  of	  venous	  
identity	  without	  a	  concomitant	  rise	  in	  ephrin-­‐b2	  (21).	  These	  experiments	  also	  
identified	  that	  the	  majority	  of	  Eph-­‐B4	  expression	  originated	  in	  the	  endothelium	  
although	  there	  was	  some	  Eph-­‐B4	  expression	  in	  smooth	  muscle	  cell	  layers.	  The	  loss	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of	  Eph-­‐B4	  expression	  was	  also	  seen	  in	  patent	  saphenous	  vein	  grafts	  excised	  from	  
transplanted	  human	  hearts	  (21).	  	  
	   To	  test	  whether	  Eph-­‐B4	  signaling	  could	  be	  manipulated	  during	  vein	  graft	  
adaptation	  vein	  grafted	  mice	  were	  injected	  with	  multiple,	  systemic	  injections	  of	  
ephrin-­‐B2,	  intimal	  thickness	  of	  the	  vein	  graft	  could	  be	  reduced	  (41).	  Further	  
demonstrating	  Eph-­‐B4’s	  role	  vein	  graft	  adaptation,	  Eph-­‐B4	  heterozygous	  knockout	  
vein	  grafts	  demonstrated	  increased	  intimal	  thickness	  compared	  to	  wild-­‐type	  vein	  
grafts.	  Muto	  et	  al	  also	  demonstrated	  that	  ephrin-­‐b2/fc	  activated	  Eph-­‐B4	  co-­‐localized	  
with	  cav-­‐1	  and	  that	  cav-­‐1	  heterozygous	  knockout	  mice	  also	  demonstrated	  increased	  
intimal	  thickening	  implying	  that	  cav-­‐1	  is	  involved	  in	  downstream	  transduction	  of	  
Eph-­‐B4	  activation.	  Finally,	  while	  no	  definitive	  mechanism	  was	  determined	  for	  the	  
reduction	  in	  wall	  thickness	  with	  Eph-­‐B4	  activation,	  it	  was	  observed	  that	  ephrin-­‐
b2/fc	  treatments	  increased	  nitric	  oxide	  signaling	  in	  vitro	  and	  caused	  a	  preservation	  
of	  Eph-­‐B4	  protein	  within	  the	  endothelium	  of	  the	  vein	  graft	  in	  vivo.	  	  
	   To	  further	  investigate	  the	  role	  of	  Eph-­‐B4	  in	  vein	  graft	  adaptation,	  endothelial	  
functions	  were	  examined	  in	  heterozygote	  knockout	  mouse	  lung	  endothelial	  cells	  
under	  the	  hypothesis	  that	  knockout	  endothelial	  cells	  would	  resemble	  vein	  grafts	  
undergoing	  early	  adaptation.	  Theses	  studies	  demonstrated	  that	  knockout	  
endothelial	  cells	  did	  indeed	  exhibit	  less	  proliferation,	  migration,	  and	  nitric	  oxide	  
release	  than	  wild-­‐type	  cells	  while	  secreting	  more	  of	  the	  smooth	  muscle	  cell	  
mitogens	  VEGF-­‐A,	  PDGF-­‐BB,	  and	  TGF-­‐β	  (42).	  Jadlowiec	  et	  al	  also	  demonstrated	  that	  
while	  VEGF-­‐A	  upregulation	  occurred	  in	  both	  the	  knockout	  endothelial	  cells	  and	  
early	  vein	  grafts,	  subsequent	  AKT	  phosphorylation	  was	  seen	  in	  the	  endothelial	  cells	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and	  not	  whole	  vein	  grafts	  while	  ERK	  phosphorylation	  was	  seen	  in	  the	  vein	  grafts	  
and	  not	  endothelial	  cells.	  These	  findings	  seem	  to	  suggest	  that	  VEGF-­‐A	  which	  is	  also	  
known	  to	  downregulate	  Eph-­‐B4	  may	  have	  differential	  effects	  on	  smooth	  muscle	  and	  
endothelial	  cells	  (42,	  43).	  	  
	   To	  summarize,	  Eph-­‐B4	  and	  its	  ligand	  ephrin-­‐B2	  are	  embryologic	  
determinants	  of	  venous	  and	  arterial	  fate	  in	  the	  developing	  vasculature.	  Eph-­‐B4	  
which	  is	  predominantly,	  but	  not	  exclusively,	  expressed	  in	  the	  adult	  venous	  
endothelium	  is	  lost	  during	  vein	  graft	  adaptation.	  Eph-­‐B4	  reduction	  in	  the	  
endothelium	  as	  simulated	  with	  heterozygote	  knockouts	  is	  associated	  with	  many	  of	  
the	  factors	  known	  to	  be	  active	  in	  vein	  graft	  adaptation	  and	  neointima	  formation	  
such	  as	  loss	  of	  endothelium,	  loss	  of	  nitric	  oxide	  secretion,	  and	  secretion	  of	  smooth	  
muscle	  growth	  factors.	  Finally	  exogenous	  Eph-­‐B4	  activation	  with	  soluble	  ephrin-­‐
B2/Fc	  can	  reduce	  neointimal	  formation	  in	  vivo	  and	  vein	  derived	  from	  Eph-­‐B4	  
heterozygote	  knockout	  mice	  leads	  to	  an	  increase	  in	  neointima	  formation.	  	  
	  
Specific	  Aims	  of	  this	  Investigation	  	  
	   With	  a	  promising	  role	  for	  Eph-­‐B4	  activation	  in	  reducing	  neointimal	  
hyperplasia	  established	  in	  mice,	  the	  next	  step	  is	  to	  determine	  whether	  these	  
findings	  translate	  to	  human	  tissue.	  Testing	  of	  potential	  therapeutics	  in	  vitro	  in	  
human	  samples	  is	  essential	  not	  only	  to	  ensure	  that	  the	  findings	  translate	  across	  
species	  but	  also	  because	  there	  exists	  very	  real	  biologic	  differences	  between	  vein	  
graft	  tissue	  derived	  from	  a	  mouse	  and	  that	  harvested	  from	  a	  vasculopathic	  patient	  
requiring	  bypass	  surgery.	  Furthermore,	  while	  Eph-­‐B4	  activation	  via	  ephrin-­‐B2	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ligand	  activation	  appears	  an	  attractive	  therapeutic	  target,	  multiple	  intra-­‐peritoneal	  
injections	  in	  humans	  as	  an	  adjuvant	  therapy	  to	  bypass	  surgery	  poses	  obvious	  
problems	  such	  as	  unanticipated	  systemic	  effects,	  patient	  discomfort,	  and	  increased	  
chance	  of	  infection.	  Thus	  ,it	  is	  necessary	  to	  investigate	  alternative	  forms	  of	  drug	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Purpose:	  	  
To	  determine	  whether	  the	  reduction	  in	  neointimal	  hyperplasia	  development	  in	  vein	  
grafts	  with	  Eph-­‐B4	  activation	  seen	  in	  a	  mouse	  model	  will	  translate	  to	  human	  tissue.	  
	  
Hypothesis	  1:	  Eph-­‐B4	  activation	  will	  reduce	  neointimal	  hyperplasia	  in	  human	  
saphenous	  vein	  in	  vitro	  
	  
	   Specific	  Aim	  #1:	  To	  compare	  ephrin-­‐b2/fc	  treated	  and	  untreated	  human	  
	   saphenous	  vein	  rings	  in	  an	  organ	  culture	  model	  of	  neointimal	  hyperplasia	  	  
	  
Hypothesis	  2:	  Eph-­‐B4	  activation	  causes	  a	  reduction	  in	  the	  loss	  of	  Eph-­‐B4	  
during	  vein	  graft	  adaptation	  	  
	  
	   Specific	  Aim	  #1:	  To	  compare	  the	  expression	  of	  levels	  of	  treated	  and	  
	   untreated	  vein	  rings	  to	  determine	  if	  Eph-­‐B4	  activation	  reduces	  Eph-­‐B4	  loss	  
	  
Hypothesis	  3:	  Eph-­‐B4	  signaling	  in	  human	  endothelium	  will	  recapitulate	  
findings	  in	  mouse	  endothelium	  
	  
	   Specific	  Aim	  #1:	  To	  compare	  levels	  of	  phosphorylated	  AKT	  and	  ERK	  in	  
	   ephrin-­‐b2/fc	  treated	  and	  untreated	  endothelium	  	  
	  
	   Specific	  Aim	  #2:	  To	  demonstrate	  that	  ephrin-­‐b2/fc	  activation	  of	  Eph-­‐B4	  
	   proceeds	  through	  a	  cav-­‐1	  dependent	  manner	  	  
	  
Hypothesis	  4:	  Endothelial	  activation	  of	  Eph-­‐B4	  is	  possible	  with	  a	  one	  time	  
adventitial	  application	  of	  ephrin-­‐B2/Fc	  to	  human	  veins.	  	  
	  
	   Specific	  Aim	  #1:	  To	  demonstrate	  endothelial	  Eph-­‐B4	  activation	  following	  
	   application	  of	  pluronic	  gel	  containing	  ephrin-­‐B2/Fc	  to	  the	  adventitia	  of	  a	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Methods:	  	  
Saphenous	  Vein	  Organ	  Culture	  	  
	   Excess	  saphenous	  vein	  remnants	  were	  secured	  from	  patients	  undergoing	  
coronary	  artery	  bypass	  grafts	  (HIC	  protocol	  #9908011041)	  at	  a	  large	  academic	  
medical	  center	  following	  the	  completion	  of	  surgery.	  They	  were	  transported	  in	  ice-­‐
cold	  low	  glucose	  Dulbecco’s	  Modified	  Eagle’s	  Medium	  (Gibco,	  Carlsbad,	  CA)	  and	  
immediately	  cut	  into	  5-­‐10	  millimeters	  (mm)	  cross	  sectional	  rings.	  Day	  0	  samples	  
were	  immediately	  fixed	  in	  formalin.	  Additional	  samples	  from	  adjacent	  sections	  of	  
the	  vein	  were	  placed	  in	  12	  well	  tissue	  culture	  dishes	  with	  Roswell	  Park	  Memorial	  
Institute	  (RPMI	  1640,	  Gibco)	  supplemented	  with	  30%	  fetal	  bovine	  serum,	  1%	  L-­‐
glutamine,	  1%	  penicillin/streptomycin	  for	  2	  weeks	  at	  37	  degrees	  Celsius	  (C).	  In	  a	  
blinded	  fashion	  the	  media	  was	  either	  supplemented	  with	  recombinant	  human	  
ephrin-­‐B2/Fc	  chimera	  (R&D	  Systems,	  Minneapolis,	  MN)	  at	  a	  concentration	  of	  2	  
micrograms	  (μg)/ml	  	  or	  not.	  The	  media	  was	  changed	  every	  2-­‐3	  days	  and	  samples	  
were	  fixed	  in	  formalin	  or	  frozen	  in	  optimal	  cutting	  temperature	  compound	  (Tissue-­‐
Tek	  Sakura	  Finetek,	  Torrance,	  CA).	  	  
	  
Histology	  and	  Morphometric	  Measurements	  
	   Following	  formalin	  fixation	  samples	  were	  transported	  in	  70%	  ethanol	  to	  the	  
Yale	  Research	  Histology	  Laboratory	  (New	  Haven,	  CT)	  embedded	  in	  paraffin,	  7	  
micrometer	  (μm)	  sections	  were	  cut	  and	  slides	  were	  stained	  with	  Verhoeff-­‐Van	  
Gieson	  (VVG)	  elastin	  stain,	  hematoxylin	  and	  eosin	  (H&E),	  or	  terminal	  
deoxynucleotidyl	  transferase	  dUTP	  nick	  end	  labeling	  (TUNEL).	  Slides	  were	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examined	  and	  multiple	  pictures	  were	  taken	  per	  sample.	  Using	  ImageJ	  software	  (NIH,	  
Bethesda,	  MD)	  the	  area	  of	  intima	  and	  media	  were	  measured	  in	  4	  quadrants	  of	  the	  
vein	  ring.	  Intima	  was	  defined	  as	  the	  area	  on	  the	  luminal	  side	  of	  the	  internal	  elastic	  
lamina	  or	  areas	  of	  disordered	  smooth	  muscle	  cell	  proliferation	  luminal	  to	  the	  
ordered,	  linear	  smooth	  muscle	  cell	  layer.	  The	  overall	  area	  of	  intima	  was	  divided	  by	  
the	  area	  of	  the	  media	  to	  yield	  and	  an	  intima:media	  (I:M)	  ratio.	  	  
	  
Quantitative	  reverse	  transcriptase	  polymerase	  chain	  reaction	  	  
	   RNA	  was	  isolated	  vein	  rings	  by	  taking	  OCT	  embedded	  samples	  and	  collecting	  
approximately	  50	  10	  μm	  thick	  sections	  cut	  on	  a	  microtome.	  These	  sections	  were	  
washed	  twice	  with	  cold,	  RNAse,	  DNAse	  free	  water	  to	  dissolve	  OCT.	  The	  veins	  were	  
then	  homogenized	  by	  repeatedly	  aspirating	  the	  lysate	  through	  a	  22	  gauge	  needle	  in	  
beta-­‐meracptoethanol	  containing	  lysis	  buffer	  as	  provided	  in	  the	  RNeasy	  Mini	  Kit	  
(Qiagen,	  Hilden,	  Germany).	  The	  remainder	  of	  the	  isolation	  and	  purification	  steps	  
were	  carried	  as	  specified	  in	  the	  manufacturer’s	  instructions.	  RNA	  isolation	  from	  cell	  
culture	  was	  also	  carried	  out	  according	  to	  manufacturer’s	  instructions	  using	  the	  
RNeasy	  Mini	  Kit.	  RNA	  quantification	  and	  purity	  assessment	  was	  done	  using	  
nanodrop	  spectrophotometer	  measurement.	  Reverse	  transcription	  was	  performed	  
using	  the	  SuperScript	  III	  First-­‐Strand	  Synthesis	  Supermix	  (Invitrogen,	  Carlsbad,	  CA).	  
Real-­‐time	  quantitative	  .	  Real-­‐time	  quantitative	  PCR	  was	  performed	  using	  SYBR	  
Green	  Supermix	  and	  the	  iQ5	  Real-­‐Time	  PCR	  Detection	  system	  (Bio-­‐Rad	  
Laboratories,	  Hercules,	  CA).	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   Primers	  for	  specific	  genes	  are	  presented	  in	  table	  1.	  Primers	  were	  designed	  
using	  publicly	  available	  online	  software	  and	  oligos	  were	  synthesized	  by	  the	  Keck	  
Oligo	  Synthesis	  Facility	  (New	  Haven,	  CT).	  Correct	  target	  size	  amplification	  and	  
exclusion	  of	  nonspecific	  amplification	  was	  confirmed	  by	  performing	  electrophoresis	  
on	  amplification	  products	  on	  2%	  agarose	  gel	  as	  well	  as	  performing	  melt	  curve	  
analysis.	  For	  analysis	  reactions	  were	  normalized	  to	  GAPDH	  as	  a	  housekeeping	  gene.	  	  
Gene	   	   Sequence	  
GAPDH	   5’-­‐>3’	   GAGAAGGCTGGGGCTCATTT	  
	   3’-­‐>5’	   AGTGATGGCATGGACTGTGG	  
Eph-­‐B4	   5’-­‐>3’	   ATGCCCGTCATGATTCTCAC	  
	   3’-­‐>5’	   GGAAAGGCCAAAGTCAGACA	  
Ephrin-­‐B2	   5’-­‐>3’	   AACTGTGCCAAACCAGACCA	  
	   3’-­‐>5’	   GCAGAACTTGCATCTTGTCCA	  
Osteopontin	  (OPN)	  	   5’-­‐>3’	   CTGCCAGCAACCGAAGTTTT	  
	   3’-­‐>5’	   TCCTCGCTTTCCATGTGTGA	  
Table	  1.	  Primers	  employed	  in	  qPCR	  reactions.	  	  
	  
Human	  Umbilical	  Venous	  Endothelial	  Cell	  (HUVEC)	  culture	  
	   HUVEC	  cells	  were	  cultured	  in	  Endothelial	  Basal	  Medium	  with	  Bulletkit	  
growth	  factors	  (Lonza,	  Basel,	  Switzerland)	  supplemented	  with	  15%	  fetal	  bovine	  
serum	  and	  1%	  penicillin/streptomycin.	  Cells	  were	  grown	  on	  either	  glass	  coverslips	  
or	  6	  well	  plates	  coated	  with	  0.1%	  gelatin.	  Cells	  were	  assayed	  between	  passages	  2-­‐5.	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Prior	  to	  stimulation,	  growth	  medium	  was	  removed	  and	  cells	  were	  placed	  in	  serum	  
free	  starvation	  media	  for	  at	  least	  3	  hours.	  	  
	  
Western	  blot	  and	  immunoprecipitation	  
	   Ephrin-­‐b2/fc	  was	  pre-­‐clustered	  with	  human	  IgG/Fc	  (Sigma	  Aldrich,	  St.	  Louis,	  
MO)	  at	  a	  5:1	  molar	  ratio	  for	  20	  minutes	  at	  37	  C	  and	  then	  cells	  were	  treated	  with	  the	  
clustered	  ligand.	  Following	  stimulation,	  cells	  were	  washed	  with	  ice	  cold	  PBS	  and	  
then	  lysed	  using	  a	  RIPA	  buffer	  supplemented	  with	  protease	  inhibitor	  cocktail	  
(Sigma-­‐Aldrich,	  St	  Louis,	  MO)	  and	  phosphatase	  inhibitors	  (Thermo	  Scientific,	  
Waltham,	  MA).	  Protein	  concentrations	  were	  assessed	  using	  a	  colorimetric	  assay	  
(Bio-­‐rad,	  Hercules,	  CA)	  and	  then	  matching	  amounts	  of	  protein	  were	  run	  on	  a	  SDS-­‐
PAGE	  gel	  and	  then	  transferred	  to	  a	  nitrocellulose	  membrane.	  Following	  blocking	  
with	  2%	  bovine	  serum	  albumin,	  membranes	  were	  probed	  overnight	  with	  primary	  
antibodies	  listed	  at	  the	  end	  of	  this	  section.	  Membranes	  were	  developed	  using	  
Supersignal	  West	  Pico	  kit	  (Thermo	  Scientific,	  Waltham,	  MA).	  Immunoprecipitation	  
was	  performed	  by	  incubating	  at	  least	  200	  μg	  of	  protein	  with	  a	  phosphor-­‐tyrosine	  
antibody	  bound	  sepharose	  bead	  overnight	  and	  then	  western	  blot	  conducted	  as	  
above.	  	  
	  
Con-­‐focal	  and	  immunofluorescence	  microscopy	  	  
	   HUVEC	  cells	  were	  plated	  on	  glass	  coverslips,	  serum	  starved,	  and	  treated.	  
They	  were	  fixed	  in	  10%	  neutral	  buffered	  formalin	  for	  15	  minutes,	  washed,	  and	  the	  
cell	  membranes	  were	  made	  permeable	  by	  brief	  treatment	  with	  triton-­‐x-­‐100	  and	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then	  blocked	  with	  goat	  serum	  and	  exposed	  to	  primary	  antibody	  overnight.	  They	  
were	  treated	  with	  alexa-­‐flouro	  488,	  568,	  and	  647	  secondary	  antibodies	  and	  
mounted	  with	  a	  DAPI	  containing	  media.	  They	  were	  examined	  using	  AxioImager	  A1	  
(Carl	  Zeiss	  Inc,	  Oberkochen,	  Germany)	  or	  a	  TCS	  SP5	  II	  (Leica,	  Solms,	  Germany).	  Vein	  
samples	  undergoing	  immunofluorescence	  were	  fixed	  with	  formalin	  and	  then	  
embedded	  in	  paraffin	  and	  cut	  into	  5	  μm	  sections	  and	  placed	  on	  slides.	  Following	  
deparaffinization,	  antigen	  retrieval	  was	  conducted	  by	  boiling	  with	  10mM	  citric	  acid	  
with	  0.05	  tween	  pH	  6	  for	  20	  minutes.	  Blocking	  was	  conducted	  with	  goat	  serum	  and	  
primary	  antibody	  was	  applied	  overnight.	  Secondary	  antibodies	  were	  applied	  as	  
above.	  Autofluoresence	  Elliminator	  Reagent	  (Millipore,	  Billerica,	  MA)	  was	  used	  and	  
then	  sections	  were	  mounted	  in	  DAPI	  containing	  mounting	  media	  and	  imaged	  on	  an	  
AxioImager	  A1	  (Carl	  Zeiss	  Inc,	  Oberkochen,	  Germany)	  	  	  
	   Primary	  antibodies	  to	  the	  following	  antigens	  were	  obtained	  as	  follows:	  Eph-­‐
B4	  catalog	  #64820,	  Caveolin-­‐1	  catalog	  #17052	  were	  obtained	  from	  Abcam	  
(Cambridge,	  England).	  Antibodies	  to	  phosphorylated	  AKT	  ser	  473	  Catalog	  #9271,	  
phosphorylated	  ENOS	  ser	  1177	  catalog	  #9571,	  GAPDH	  catalog	  #2118,	  
phosphorylated-­‐tyrosine	  conjugated	  to	  sepharose	  beads	  Catalog	  #9419	  were	  
obtained	  from	  Cell	  Signaling	  Technologies	  (Danvers,	  Ma).	  Antibody	  to	  phosphor-­‐
tyrosine	  residues	  catalog	  #05-­‐1050	  was	  obtained	  from	  Millipore	  (Billerica,	  MA).	  
Antibody	  to	  total	  ENOS	  catalog	  #BD610296	  and	  phosphorylated	  cav-­‐1	  (tyr14)	  
#BD611338	  were	  obtained	  from	  BD	  Biosciences	  (Franklin	  Lakes,	  NJ).	  
	  
Pluronic	  Gel	  experiments:	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   Ephrin-­‐B2/Fc	  was	  dissolved	  in	  a	  30%	  pluronic	  gel	  (Sigma-­‐Aldrich,	  St	  Louis,	  
MO).	  Excess	  saphenous	  vein	  was	  taken	  from	  the	  OR	  in	  ice-­‐cold	  low	  glucose	  DMEM	  
and	  the	  vein	  was	  placed	  in	  the	  Bioreactor	  (pictured	  in	  Appendix	  A)	  set	  up	  consisting	  
of	  a	  glass	  chamber	  (fabricated	  at	  the	  Yale	  Scientific	  Glass	  Shop,	  New	  Haven,	  CT)	  	  
with	  vein	  section	  attached	  to	  glass	  connector	  which	  were	  connected	  to	  a	  glass	  
compliance	  chamber	  on	  either	  end	  to	  equalize	  pressure	  in	  the	  system,	  and	  an	  intake	  
0.22µm	  air	  filter	  on	  the	  distal	  chamber.	  A	  digital	  programmable	  roller-­‐pump	  (Cole	  
Parmer,	  Vernon	  Hills,	  IL)	  was	  used	  to	  push	  media	  along	  the	  system	  which	  was	  
placed	  in	  a	  37ºC	  incubator.	  Intraluminal	  fluid	  consisted	  of	  Endothelial	  Growth	  
Medium	  (EGM-­‐2	  Lonza,	  Basel,	  Switzerland)	  thickened	  with	  Xanthum	  Gum	  (sigma)	  to	  
a	  viscosity	  of	  3.8	  cP;	  .	  XG	  solution	  was	  autoclaved	  to	  assure	  sterility	  before	  
composition	  with	  media	  base.	  Extraluminal	  fluid	  consisted	  of	  DMEM	  supplemented	  
with	  30%	  fetal	  bovine	  serum.	  Specimens	  were	  harvested	  starting	  approximately	  1	  
cm	  from	  the	  origin	  of	  the	  attached	  connector	  in	  order	  to	  avoid	  areas	  of	  turbulent	  
flow	  at	  this	  transition	  point.	  
	  
Statistics:	  
	   Statistical	  analysis	  including	  one	  way	  ANOVA	  and	  paired	  T	  test	  were	  
performed	  using	  GraphPad	  version	  6.0a	  for	  MAC	  OS	  X,	  GraphPad	  Software	  (La	  Jolla,	  
CA).	  A	  p	  value	  of	  less	  than	  0.05	  was	  considered	  significant.	  Means	  are	  reported	  as	  
arithmetic	  means	  with	  standard	  errors	  of	  the	  means	  following.	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Results:	  	  
Validating	  unbiased	  method	  of	  measuring	  intima:media	  ratios.	  	  
	   The	  development	  of	  neointimal	  hyperplasia	  can	  be	  irregular	  around	  the	  
luminal	  surface	  of	  a	  vessel.	  In	  previous	  studies	  using	  intima:media	  ratios	  to	  measure	  
the	  development	  of	  neointimal	  hyperplasia,	  linear	  measurements	  of	  the	  intima	  and	  
media	  have	  been	  used.	  Various	  schemes	  have	  been	  used	  to	  place	  the	  exact	  points	  of	  
measurement	  in	  an	  unbiased	  manner	  such	  as	  8	  equally	  spaced	  radial	  
measurements.	  However,	  there	  is	  still	  the	  chance	  of	  inadvertent	  bias	  to	  affect	  the	  
process	  since	  placing	  the	  exact	  point	  of	  measurement	  requires	  the	  observer	  to	  draw	  
two	  lines	  on	  a	  computer	  screen.	  The	  placement	  of	  these	  lines	  can	  drastically	  affect	  
the	  measurement.	  Moreover	  when	  the	  vein	  is	  not	  a	  perfect	  circle	  radial	  distribution	  
of	  the	  lines	  is	  not	  straightforward.	  Therefore	  we	  investigated	  whether	  
measurements	  of	  the	  area	  of	  the	  intima	  and	  the	  media	  could	  be	  more	  
comprehensive	  and	  reduce	  the	  chance	  of	  bias.	  	  
	   Vein	  rings	  from	  three	  donors	  were	  put	  in	  organ	  culture	  for	  14	  days.	  Two	  
strategies	  for	  measuring	  the	  intima:media	  ratio	  were	  employed.	  Four	  equally	  spaced	  
radial	  lines	  were	  drawn	  to	  designate	  the	  points	  to	  measure	  the	  linear	  intima	  and	  
media	  lengths	  (Fig	  1a).	  On	  the	  same	  sample	  four	  quadrants	  were	  designated	  and	  
then	  total	  area	  of	  the	  intima	  and	  media	  were	  measured	  in	  these	  quadrants	  as	  
outlined	  by	  the	  lines	  (Fig	  1b).	  Using	  both	  the	  linear	  and	  area	  methods	  of	  measuring	  
mean	  intima:media	  ratios	  increased	  over	  time	  in	  the	  same	  samples	  (Fig	  1	  c,d).	  Mean	  
intima:media	  ratios	  increased	  over	  time	  in	  both	  the	  linear	  and	  area	  measurements	  
by	  approximately	  the	  same	  amount	  (Fig	  1	  e).	  Finally	  the	  percent	  change	  in	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intima:media	  ratio	  from	  day	  0	  was	  similar	  between	  both	  methods	  for	  individual	  
samples	  differing	  by	  only	  20.6%	  ±	  1.4%	  (Fig	  1	  f).	  Given	  the	  similar	  results	  both	  as	  a	  
group	  and	  with	  each	  individual	  sample	  between	  the	  two	  methods	  we	  concluded	  that	  
the	  two	  results	  were	  comparable.	  With	  the	  smaller	  chance	  for	  any	  inadvertent	  bias	  
in	  the	  area	  method,	  we	  decided	  to	  proceed	  with	  the	  area	  strategy	  and	  as	  well	  to	  
blind	  the	  observer.	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Figure	  1.	  Comparison	  of	  linear	  versus	  area	  measurement	  method	  for	  determining	  
intima:media	  ratios.	  Depiction	  of	  linear	  (a)	  and	  area	  (b)	  methods.	  Individual	  sample	  
change	  in	  intima:media	  ratio	  change	  by	  linear	  (c)	  and	  area	  (d)	  methods.	  Average	  
increase	  in	  intima:media	  ratios	  over	  time	  (e).	  Comparing	  individual	  percent	  change	  
from	  day	  0	  for	  each	  method	  (f).	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Hypothesis	  #1:	  Treatment	  of	  saphenous	  vein	  rings	  with	  soluble	  ephrin-­‐B2/Fc	  will	  
decrease	  the	  development	  of	  neointimal	  hyperplasia	  in	  organ	  culture.	  	  
	  
	   To	  examine	  the	  effect	  of	  exogenous	  Eph-­‐B4	  stimulation	  on	  the	  development	  
of	  neointimal	  hyperplasia	  in	  human	  saphenous	  vein,	  vein	  rings	  from	  the	  same	  donor	  
and	  adjacent	  section	  of	  vein	  were	  placed	  in	  organ	  culture	  for	  14	  days	  with	  or	  
without	  soluble	  Ephrin-­‐B2/Fc	  the	  activating	  ligand	  for	  Eph-­‐B4.	  Given	  the	  variability	  
in	  the	  size	  and	  pre-­‐existing	  intimal	  hyperplasia	  pre-­‐culture,	  intima:media	  (I:M)	  
ratios	  were	  used	  to	  measure	  the	  development	  of	  the	  neointimal	  hyperplasia	  in	  the	  
vein	  rings.	  The	  mean	  baseline	  I:M	  ratio	  was	  0.456	  ±	  0.097	  (n=19).	  Over	  14	  days	  in	  
organ	  culture	  this	  ratio	  increased	  to	  0.726	  ±	  0.142	  (n=19)	  in	  untreated	  veins	  and	  
0.630	  ±	  0.132	  (n=19)	  (Fig	  2c).	  Using	  paired	  T-­‐tests,	  these	  results	  demonstrated	  a	  
significant	  difference	  in	  I:M	  ratios	  between	  the	  matched	  controls	  in	  the	  treated	  and	  
untreated	  vein	  rings	  after	  14	  days	  in	  organ	  culture	  (Fig	  2c).	  There	  was	  a	  significant	  
increase	  in	  I:M	  ratios	  between	  the	  baseline	  group	  and	  both	  treated	  and	  untreated	  	  
day	  group.	  The	  mean	  individual	  percentage	  increase	  in	  intima:media	  ratio	  from	  day	  
0	  to	  day	  14	  was	  78.43	  ±	  23.34%	  for	  untreated	  veins	  and	  53.09	  ±	  21.40%	  for	  treated	  
veins	  (Fig	  2e)	  .Examination	  of	  individual	  matched	  controls	  revealed	  variability	  in	  
the	  response	  to	  treatment.	  13	  of	  19	  matched	  pairs	  saw	  a	  reduction	  in	  the	  increase	  of	  
I:M	  ratio	  over	  time	  in	  the	  treatment	  group,	  however,	  six	  of	  the	  nineteen	  treated	  
rings	  demonstrated	  no	  change	  or	  even	  a	  slight	  increase	  in	  I:M	  ratio	  between	  the	  
treated	  and	  untreated	  vein	  rings	  (Fig	  2	  d).	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Figure	  2.	  Ephrin-­‐B2/Fc	  treatment	  reduces	  intima:media	  ratios	  in	  saphenous	  vein	  
organ	  culture.	  Neointima	  formation	  in	  untreated	  (a)	  and	  treated	  (b)	  vein	  rings.	  The	  
average	  intima:media	  ratios	  for	  baseline,	  untreated,	  and	  treated	  vein	  rings	  (c).	  
Treated	  and	  untreated	  samples	  matched	  pairs	  compared	  at	  day	  14	  (d).	  Percent	  
increase	  of	  intima:media	  ratios	  from	  baseline	  for	  treated	  and	  untreated	  veins	  (e).	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Hypothesis	  #2:	  Treatment	  of	  saphenous	  vein	  rings	  in	  culture	  with	  exogenous	  ephrin-­‐
B2/Fc	  will	  preserve	  Eph-­‐B4	  expression	  levels.	  	  
	   To	  examine	  whether	  Eph-­‐B4	  expression	  levels	  would	  be	  preserved	  in	  ephrin-­‐
B2/Fc	  treated	  vein	  rings	  quantitative	  polymerase	  chain	  reaction	  (qPCR)	  assays	  were	  
performed	  on	  vein	  ring	  lysates.	  Consistent	  with	  previous	  in	  vivo	  results,	  Eph-­‐B4	  and	  
ephrin-­‐B2	  mRNA	  expression	  fell	  over	  time	  in	  organ	  culture	  (Fig	  3).	  There	  was	  
however	  no	  significant	  difference	  in	  Eph-­‐B4	  levels	  in	  the	  ephrin-­‐B2/Fc	  treated	  and	  
untreated	  vein	  rings.	  To	  demonstrate	  that	  the	  loss	  of	  Eph-­‐B4	  and	  ephrin-­‐B2	  gene	  
expression	  did	  not	  represent	  a	  global	  loss	  of	  mRNA	  production,	  osteopontin	  levels	  
were	  examined.	  Osteoponin	  levels	  increased	  in	  organ	  culture	  over	  time	  and	  there	  
was	  no	  difference	  between	  treatment	  and	  non-­‐treatment	  groups.	  	  
	  
	   	  
	  
Figure	  3.	  Gene	  transcription	  levels	  of	  Eph-­‐B4,	  ephrin-­‐B2,	  osteopontin	  in	  saphenous	  
vein	  culture	  mimic	  in	  vivo	  results.	  Eph-­‐B4	  (a),	  ephrin-­‐B2	  (b),	  osteopontin	  (c)	  gene	  
transcription	  levels	  of	  baseline,	  treated,	  and	  untreated	  vein	  rings.	  	  
	  
Hypothesis	  #3:	  Treatment	  of	  endothelial	  cells	  in	  culture	  with	  exogenous	  ephrin-­‐B2/Fc	  
will	  cause	  increase	  in	  Eph-­‐B4	  expression.	  	  
	   Having	  not	  found	  any	  difference	  in	  reduction	  of	  Eph-­‐B4	  expression	  in	  the	  
ephrin-­‐B2/Fc	  treated	  vein	  rings,	  we	  hypothesized	  that	  since	  the	  majority	  of	  the	  
mass	  and	  thus	  mRNA	  of	  the	  vein	  rings	  was	  smooth	  muscle	  cell	  and	  adventitia	  and	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not	  endothelium	  after	  14	  days	  in	  organ	  culture	  some	  ephrin-­‐B2/Fc	  induced	  
endothelial	  cell	  specific	  gene	  expression	  changes	  may	  have	  been	  obscured.	  To	  
determine	  if	  this	  was	  the	  case	  Human	  Umbilical	  Venous	  Endothelial	  Cells	  (HUVECs)	  
were	  treated	  with	  ephrin-­‐B2/Fc	  and	  their	  Eph-­‐B4	  gene	  expression	  levels	  were	  
assessed	  (Fig	  4).	  There	  was	  no	  change	  in	  Eph-­‐B4	  expression	  between	  the	  control	  
and	  treatment	  groups.	  	  
	  
	  
Figure	  4.	  Ephrin-­‐B2/Fc	  treatment	  does	  not	  increase	  Eph-­‐B4	  expression	  in	  HUVEC	  
cells.	  	  
	  
Hypothesis	  #4:	  Ephrin-­‐B2/Fc	  treatment	  of	  HUVECs	  will	  lead	  to	  Eph-­‐B4	  
phosphorylation	  and	  downstream	  signaling	  changes	  in	  AKT,	  cav-­‐1,	  and	  ENOS.	  	  	  
	   Since	  ephrin-­‐B2/Fc	  did	  not	  alter	  Eph-­‐B4	  transcription	  levels,	  we	  sought	  to	  
assay	  its	  effect	  on	  Eph-­‐B4	  phosphorylation	  and	  other	  downstream	  signaling	  
cascades	  in	  endothelial	  cells.	  As	  expected	  ephrin-­‐B2/Fc	  treatments	  caused	  a	  strong	  
increase	  in	  Eph-­‐B4	  phosphorylation	  in	  HUVECs	  cells	  (Fig	  5a).	  Ephrin-­‐B2/Fc	  
treatments	  also	  caused	  an	  increase	  in	  phosphorylated	  AKT	  (ser473)	  and	  cav-­‐1	  
(tyr14)	  over	  time	  (Fig	  5b,	  c).	  Phosphorylated	  ENOS	  (ser1177)	  expression	  also	  
appeared	  to	  be	  upregulated	  although	  not	  to	  the	  degree	  of	  AKT	  or	  cav-­‐1.	  Using	  con-­‐
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focal	  microscopy	  we	  observed	  that	  ephrin-­‐B2/Fc	  treatments	  caused	  an	  increase	  in	  
co-­‐localization	  between	  caveolin-­‐1	  and	  Eph-­‐B4	  confirming	  previous	  observations	  
made	  in	  mice	  (Fig	  6).	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Figure	  5.	  Ephrin-­‐B2/Fc	  treatment	  of	  HUVEC	  leads	  to	  Eph-­‐B4	  phosphorylation	  and	  
downstream	  signaling	  changes.	  Immunoprecipitation	  of	  HUVEC	  treated	  with	  ephrin-­‐
b2/Fc:	  initial	  pull	  down	  with	  phospho-­‐tyrosine	  and	  then	  probed	  for	  Eph-­‐B4	  (a).	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Ephrin-­‐B2/Fc	  treated	  cells	  demonstrating	  increase	  of	  phosphorylated	  AKT	  (ser473)	  
over	  time	  (b).	  HUVEC	  cells	  treated	  with	  ephrin-­‐b2/fc	  assessed	  for	  phosphorylated	  
ENOS	  (ser1177)	  and	  Cav-­‐1	  (tyr14)	  (c).	  Quantification	  of	  expression	  of	  phospho-­‐





Figure	  6.	  Ephrin-­‐B2/Fc	  treatment	  causes	  co-­‐localization	  of	  Cav-­‐1	  and	  Eph-­‐B4	  in	  
HUVEC	  cells.	  Untreated	  HUVEC	  cells	  (a).	  Ephrin-­‐B2/Fc	  treated	  cells	  demonstrating	  
co-­‐localization	  of	  Eph-­‐B4	  and	  cav-­‐1	  (b).	  Negative	  control	  cells	  without	  primary	  
antibody	  (c).	  	  
	  
Hypothesis	  #5:	  Endothelial	  Eph-­‐B4	  activation	  can	  be	  achieved	  with	  application	  of	  
ephrin-­‐B2/Fc	  dissolved	  in	  a	  pluronic	  gel	  applied	  to	  the	  adventitia	  of	  the	  vein.	  	  
	   Saphenous	  vein	  was	  placed	  in	  a	  bioreactor	  that	  simulated	  arterial	  flow.	  Prior	  
to	  initiation	  of	  flow	  the	  adventitia	  of	  the	  vein	  was	  treated	  with	  pluronic	  gel	  
containing	  ephrin-­‐B2/Fc	  or	  not.	  The	  gel	  was	  allowed	  to	  adhere	  to	  the	  adventitia	  of	  
the	  vein	  and	  then	  arterial	  flow	  was	  run	  for	  24	  hours.	  At	  the	  end	  of	  24	  hours	  the	  
treated	  veins	  showed	  an	  increase	  in	  co-­‐localization	  of	  Eph-­‐B4	  and	  phospho-­‐tyrosine	  
residues	  especially	  in	  the	  endothelium	  of	  the	  vein	  that	  were	  not	  present	  either	  at	  
time	  0	  or	  in	  the	  untreated	  vein	  (Fig	  7).	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Figure	  7.	  Adventitial	  delivery	  of	  ephrin-­‐B2/Fc	  causes	  eph-­‐B4	  phosphorylation.	  
Saphenous	  vein	  at	  time	  0	  (a).	  Saphenous	  vein	  treated	  with	  ephrin-­‐b2/fc	  at	  24hrs	  
with	  increased	  co-­‐localization	  of	  eph-­‐b4	  and	  phosphor-­‐tyrosine	  (b).	  Untreated	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Discussion:	  	  
	   Recent	  work	  in	  mouse	  models	  demonstrated	  that	  Eph-­‐B4	  stimulation	  with	  
ephrin-­‐B2/fc	  was	  effective	  in	  reducing	  intimal	  thickness	  during	  vein	  graft	  
adaptation	  (41).	  Thus,	  while	  Eph-­‐B4	  activation	  appears	  to	  be	  a	  promising	  
therapeutic	  target	  for	  reducing	  neointimal	  hyperplasia	  in	  vein	  grafts,	  it	  was	  
necessary	  to	  determine	  whether	  these	  findings	  in	  mice	  translated	  to	  human	  tissue.	  
Unfortunately,	  there	  are	  few	  established	  models	  to	  simulate	  vein	  graft	  adaptation	  in	  
vitro	  with	  human	  tissue.	  Since	  we	  ultimately	  wanted	  to	  evaluate	  the	  effect	  of	  Eph-­‐B4	  
stimulation	  on	  intimal	  hyperplasia	  over	  time,	  the	  saphenous	  vein	  organ	  culture	  
model	  was	  chosen,	  because	  it	  yields	  a	  histologic	  phenotype	  from	  which	  intimal	  
hyperplasia	  can	  be	  measured	  by	  tracking	  intima:media	  ratios.	  	  
	   Saphenous	  vein	  rings	  incubated	  with	  soluble	  ephrin-­‐B2/fc	  developed	  less	  
intimal	  hyperplasia	  over	  14	  days	  than	  rings	  from	  the	  same	  donor	  and	  adjacent	  
section	  of	  vein	  (Fig	  2c).	  	  The	  reduction	  in	  development	  of	  intimal	  hyperplasia	  is	  
consistent	  with	  experiments	  performed	  in	  mice	  using	  large	  systemic	  injections	  of	  
the	  ligand	  (41).	  The	  reduction	  in	  I:M	  ratios	  was	  not	  a	  universal	  effect	  as	  close	  to	  1/3	  
of	  the	  treated	  vein	  rings	  did	  not	  demonstrate	  a	  decrease	  in	  intimal	  hyperplasia	  
compared	  to	  untreated	  controls	  (Fig	  2d).	  When	  employing	  human	  samples	  it	  is	  not	  
surprising	  that	  there	  are	  variable	  responses	  to	  treatment.	  One	  of	  the	  strengths	  of	  
this	  study	  is	  that	  these	  experiments	  were	  performed	  on	  saphenous	  veins	  from	  
patients	  undergoing	  bypass	  surgery.	  Thus,	  unlike	  animal	  models	  or	  tissue	  from	  
healthy	  volunteers,	  these	  veins	  are	  representative	  of	  the	  actual	  tissue	  from	  
vasculopathic	  patients	  who	  require	  saphenous	  vein	  grafts.	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   Given	  the	  ethical	  and	  clinical	  restraints	  of	  securing	  human	  tissue,	  the	  
saphenous	  vein	  used	  in	  these	  experiments	  was	  not	  procured	  until	  the	  operation	  was	  
completed.	  It	  is	  well	  documented	  that	  surgical	  trauma,	  ischemic	  time,	  vein	  quality	  
and	  even	  vein	  harvesting	  technique	  can	  affect	  vein	  grafts	  in	  both	  in	  vitro	  assays	  of	  
relaxation,	  reactive	  oxygen	  species	  (ROS)	  generation,	  and	  even	  histologic	  
appearance,	  as	  well	  as	  their	  in	  vivo	  patency	  rates	  (44-­‐47).	  	  Accordingly,	  a	  degree	  of	  
variability	  is	  inherent	  in	  this	  experimental	  procedure.	  It	  is	  unknown	  how	  initial	  vein	  
characteristics	  such	  as	  extent	  of	  endothelial	  denudation	  would	  affect	  the	  action	  of	  
prolonged	  Eph-­‐B4	  stimulation.	  However	  since	  it	  is	  known	  that	  the	  majority	  of	  Eph-­‐
B4	  expression	  and	  thus	  hypothesized	  site	  of	  action	  is	  in	  the	  endothelium	  the	  effect	  
of	  endothelial	  damage	  on	  efficacy	  of	  Eph-­‐B4	  activation	  may	  warrant	  further	  
investigation.	  	  
	   While	  eprhin-­‐b2/fc	  Eph-­‐B4	  activation	  has	  been	  shown	  to	  affect	  multiple	  
endothelial	  processes	  including	  nitric	  oxide	  production,	  migration,	  and	  proliferation	  
as	  well	  as	  interact	  with	  AKT	  and	  MAPK	  signaling	  networks	  there	  is	  not	  yet	  a	  
definitive	  mechanism	  for	  its	  role	  in	  reducing	  intimal	  hyperplasia	  (42,	  48,	  49).	  In	  
mouse	  vein	  grafts,	  eprhin-­‐b2/fc	  stimulation	  seem	  to	  preserve	  Eph-­‐B4	  protein	  in	  the	  
endothelium	  of	  the	  vein	  grafts	  (41).	  Thus,	  we	  hypothesized	  that	  ephrin-­‐b2/fc	  
treatment	  of	  saphenous	  vein	  rings	  would	  preserve	  Eph-­‐B4	  expression,	  which	  is	  
normally	  lost	  vein	  graft	  adaptation.	  Using	  qPCR	  we	  examined	  Eph-­‐B4	  expression	  in	  
treated	  and	  untreated	  saphenous	  vein	  rings	  in	  organ	  culture	  (Fig	  3a).	  While	  both	  
Eph-­‐B4	  and	  ephrin-­‐B2	  expression	  levels	  fell	  during	  organ	  culture	  there	  was	  no	  
difference	  in	  the	  treated	  and	  untreated	  groups	  (Fig	  3a,b).	  The	  loss	  of	  Eph-­‐B4	  and	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ephrin-­‐B2	  during	  organ	  culture	  corresponded	  with	  previous	  results	  from	  mouse,	  
rat,	  and	  human	  vein	  grafts	  (21,	  41).	  To	  ensure	  that	  the	  reduction	  in	  Eph-­‐B4	  and	  
ephrin-­‐b2	  transcription	  levels	  was	  not	  due	  to	  a	  global	  reduction	  of	  gene	  
transcription	  in	  organ	  culture	  we	  also	  tested	  osteopontin	  expression,	  a	  marker	  of	  	  
venous	  adaptation,	  and	  found	  that	  it	  increased	  over	  time	  (Fig	  3c)	  (50).	  	  	  
	   Since	  the	  media	  and	  adventitia	  make	  up	  the	  vast	  majority	  of	  the	  cellular	  mass	  
of	  the	  vein	  rings	  in	  organ	  culture,	  our	  qPCR	  results	  most	  likely	  represented	  mRNA	  
transcription	  within	  smooth	  muscle	  cells	  and	  fibroblasts.	  Since	  previous	  studies	  
have	  shown	  the	  majority	  of	  Eph-­‐B4	  is	  expressed	  in	  the	  endothelium,	  we	  wanted	  to	  
more	  closely	  examine	  the	  effects	  of	  ephrin-­‐b2/fc	  on	  the	  endothelium,	  and	  thus	  
employed	  a	  HUVEC	  cell	  line	  culture	  to	  determine	  whether	  ephrin-­‐b2/fc	  increased	  
Eph-­‐B4	  expression	  in	  endothelial	  cells.	  HUVEC	  cells	  were	  treated	  with	  ephrin-­‐b2/fc	  
and	  Eph-­‐B4	  gene	  expression	  was	  assayed	  using	  qPCR,	  however,	  there	  was	  no	  
increase	  in	  Eph-­‐B4	  expression	  was	  observed	  (Fig	  4).	  	  
	   While	  ephrin-­‐b2/fc	  treatments	  have	  been	  shown	  to	  increase	  proliferation	  in	  
mouse	  endothelial	  cell	  lines,	  and	  Eph-­‐B4	  knockout	  cells	  have	  demonstrated	  reduced	  
proliferation,	  this	  does	  not	  necessarily	  require	  upregulation	  of	  Eph-­‐B4	  expression.	  
The	  preservation	  of	  Eph-­‐B4	  expression	  in	  the	  endothelium	  of	  ephrin-­‐b2/fc	  treated	  
vein	  grafts	  may	  represent	  overall	  endothelial	  recovery,	  and	  thus	  endothelial	  Eph-­‐B4	  
expression	  may	  just	  be	  a	  marker	  of	  the	  underlying	  processes	  contributing	  to	  the	  
reduction	  in	  intimal	  thickness	  rather	  than	  the	  driving	  mechanism.	  Therefore	  Eph-­‐B4	  
stimulation	  of	  endothelial	  cells	  does	  not	  necessarily	  need	  to	  lead	  to	  increased	  Eph-­‐
B4	  mRNA	  expression	  levels	  for	  Eph-­‐B4	  to	  be	  retained	  in	  the	  wall	  of	  vein	  grafts.	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   Since	  ephrin-­‐B2/fc	  treatments	  of	  saphenous	  vein	  ring	  in	  organ	  culture	  
yielded	  a	  histologic	  phenotype	  that	  was	  consistent	  to	  previous	  studies,	  we	  sought	  to	  
determine	  whether	  intracellular	  signaling	  findings	  associated	  with	  Eph-­‐B4	  
activation	  in	  mice	  also	  translated	  into	  human	  tissues.	  As	  expected	  ephrin-­‐B2/fc	  
treatment	  of	  HUVEC	  cells	  led	  to	  Eph-­‐B4	  phosphorylation	  (Fig	  5a).	  Ephrin-­‐B2/fc	  
treatment	  also	  lead	  to	  increased	  AKT	  phosphorylation	  (Fig	  5b).	  This	  finding	  is	  
consistent	  with	  previous	  experiments	  using	  human	  microvascular	  endothelial	  cells	  
isolated	  from	  the	  bowel.	  These	  endothelial	  cells	  demonstrated	  increased	  
proliferation	  and	  nitric	  oxide	  production	  in	  an	  AKT	  dependent	  manner	  in	  response	  
to	  ephrin-­‐b2/fc	  treatment	  (49).	  Given	  these	  findings	  we	  also	  sought	  to	  evaluate	  
ENOS	  phosphorylation	  which	  appeared	  to	  be	  upregulated	  with	  ephrin-­‐b2/fc	  
treatment,	  however,	  not	  significantly	  so	  when	  the	  levels	  were	  quantified.	  	  
	   Increased	  nitric	  oxide	  production	  is	  one	  likely	  possible	  mechanism	  for	  
ephrin-­‐b2/fc	  treatment	  reduction	  of	  intimal	  hyperplasia.	  Inducible	  nitric	  oxide	  
transfection	  of	  porcine	  vein	  grafts	  has	  been	  shown	  to	  decrease	  both	  intimal	  
hyperplasia	  and	  reduce	  overall	  cellular	  proliferation	  (51).	  While	  our	  results	  appear	  
to	  support	  this	  in	  that	  ephrin-­‐b2/fc	  treatments	  appeared	  to	  cause	  increases	  in	  AKT	  
and	  ENOS	  phosphorylation,	  statistical	  significance	  was	  not	  reached	  with	  the	  
densitometry.	  It	  is	  possible	  that	  HUVECs	  demonstrate	  a	  less	  dramatic	  response	  to	  
ephrin-­‐b2/fc	  treatment	  than	  adult	  endothelial	  cells	  although	  endothelial	  AKT	  
phosphorylation	  has	  been	  shown	  to	  cause	  eNOS	  phosphorylation	  and	  increased	  
nitric	  oxide	  release	  in	  HUVECs	  cells	  before	  (52).	  Thus	  while	  ephrin-­‐b2/fc	  induced	  
AKT	  and	  ENOS	  phosphorylation	  in	  human	  cells	  is	  a	  possible	  mechanism	  for	  the	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phenotype	  observed	  more	  work	  is	  needed	  to	  confirm	  this.	  Experiments	  assessing	  
direct	  nitric	  oxide	  release	  in	  response	  to	  Eph-­‐B4	  stimulation	  are	  in	  process.	  
Interestingly	  AKT	  inhibition	  via	  PTEN	  overexpression	  in	  a	  viral	  vector	  also	  lead	  to	  
reduction	  of	  intimal	  hyperplasia	  in	  a	  canine	  model	  of	  coronary	  vein	  grafting	  (30).	  
However	  this	  was	  likely	  due	  to	  inhibition	  of	  AKT	  mediated	  proliferation	  in	  smooth	  
muscle	  cells.	  	  
	   Previous	  mouse	  experiments	  demonstrated	  that	  ephrin-­‐b2/fc	  treatment	  
caused	  Eph-­‐B4	  to	  associate	  with	  caveolin-­‐1,	  a	  major	  caveolae	  coat	  protein	  critical	  in	  
caveolae	  assembly	  and	  leads	  to	  caveolin-­‐1	  phosphorylation	  (41).	  Using	  microscopy	  
we	  confirmed	  that	  ephrin-­‐b2/fc	  treatment	  causes	  co-­‐localization	  of	  Eph-­‐B4	  with	  
cav-­‐1	  in	  HUVECs	  as	  well	  (Fig	  6a).	  The	  increase	  in	  cav-­‐1	  phosphorylation	  seen	  with	  
western	  blotting	  following	  ephrin-­‐b2/fc	  treatment	  further	  strengthened	  the	  
association	  between	  Eph-­‐B4	  activation	  and	  downstream	  caveolin	  signaling	  (Fig	  
5c,e)	  In	  vivo	  confirmation	  of	  this	  comes	  from	  Muto	  et	  al	  who	  demonstrated	  that	  loss	  
of	  cav-­‐1	  eliminates	  the	  ephrin-­‐B2/fc	  intimal	  hyperplasia	  reduction	  in	  mouse	  vein	  
grafts.	  This	  experiment	  demonstrated	  the	  importance	  of	  cav-­‐1	  as	  an	  intermediate	  in	  
Eph-­‐B4	  function	  in	  the	  vein	  graft.	  Caveolae	  are	  small	  cellular	  vesicles	  that	  along	  with	  
their	  associated	  caveolin	  coat	  proteins	  have	  been	  shown	  to	  play	  important	  roles	  in	  
signal	  transduction	  especially	  in	  endothelial	  cells	  which	  are	  caveolae	  rich	  (53).	  
Interestingly	  caveolin-­‐1	  knockout	  endothelial	  cells	  show	  an	  increase	  in	  nitric	  oxide	  
production	  (54).	  Thus	  ephrin-­‐b2/fc	  activation	  of	  Eph-­‐B4	  may	  reduce	  intimal	  
hyperplasia	  in	  a	  separate	  nitric	  oxide	  independent	  manner	  as	  well.	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   Systemic	  dosing	  of	  mouse	  vein	  graft	  recipients	  with	  ephrin-­‐B2/Fc	  led	  to	  a	  
reduction	  in	  intimal	  thickness	  (41).	  Similarly	  treatment	  of	  saphenous	  vein	  rings	  
with	  eprhin-­‐B2/Fc	  dissolved	  in	  the	  organ	  culture	  media	  also	  lead	  to	  the	  desired	  
reduction	  in	  intima:media	  ratios.	  However	  we	  sought	  to	  demonstrate	  that	  Eph-­‐B4	  
activation	  was	  possible	  with	  an	  adventitial	  dosing	  of	  ephrin-­‐B2/Fc	  dissolved	  in	  a	  
pluronic	  gel.	  Using	  immunofluorescence	  microscopy	  we	  showed	  that	  Eph-­‐B4	  and	  
phospho-­‐tyrosine	  co-­‐localized	  primarily	  in	  the	  endothelium	  of	  the	  saphenous	  vein	  
was	  possible	  after	  24	  hours	  in	  an	  arterial	  flow	  simulator	  indicating	  Eph-­‐B4	  
activation	  (Fig	  7).	  	  
	   Local	  drug	  delivery	  can	  be	  advantageous	  to	  the	  bypass	  recipient.	  Drugs	  
delivered	  locally	  can	  be	  given	  at	  high	  dosages	  and	  minimize	  systemic	  effects.	  
Adventitial	  delivery	  of	  drugs	  can	  avoid	  further	  endothelial	  disruption.	  By	  necessity	  
bypass	  surgery	  exposes	  the	  anatomic	  sites	  especially	  the	  distal	  anastomosis	  where	  
subsequent	  stenosis	  is	  most	  likely	  to	  occur.	  Using	  hydrogels	  such	  as	  pluronic	  gel	  to	  
deliver	  drugs	  in	  experimental	  models	  has	  increased	  in	  recent	  years,	  however,	  
hydrogels	  tend	  to	  elute	  dissolved	  compounds	  in	  several	  days	  and	  thus	  the	  intended	  
drug	  effect	  may	  be	  transient	  and	  unable	  to	  durably	  affect	  neointimal	  hyperplasia.	  
which	  can	  develop	  over	  months	  to	  years	  (55).	  A	  limitation	  to	  our	  findings	  is	  that	  we	  
examined	  Eph-­‐B4	  activation	  after	  only	  24	  hours	  in	  the	  arterial	  bioreactor	  since	  this	  
length	  of	  time	  we	  have	  validated	  our	  bioreactor	  for	  (unpublished	  data).	  Within	  the	  
last	  year,	  ex	  vivo	  human	  saphenous	  vein	  models	  have	  been	  developed	  that	  extend	  
this	  time	  to	  1	  week	  and	  testing	  ephrin-­‐b2/Fc	  stimulation	  in	  this	  model	  is	  a	  logical	  
next	  step	  (56).	  Numerous	  labs	  including	  this	  one	  have	  employed	  viral	  vectors	  to	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increase	  desired	  gene	  expression	  to	  inhibit	  intimal	  hyperplasia	  (21,	  32,	  41,	  51).	  
While	  gene	  therapy	  for	  human	  treatment	  remains	  controversial,	  there	  are	  multiple	  
future	  directions	  to	  explore	  in	  providing	  local	  but	  durable	  Eph-­‐B4	  activation	  as	  a	  
potential	  adjunctive	  therapy	  (57).	  	  
	   There	  are	  several	  limitations	  to	  the	  saphenous	  vein	  organ	  culture	  model	  used	  
in	  these	  experiments.	  A	  vein	  ring	  in	  organ	  culture	  is	  not	  subject	  to	  flow,	  shear	  stress,	  
or	  other	  hydrostatic	  forces	  that	  have	  been	  shown	  to	  affect	  the	  development	  of	  
intimal	  hyperplasia	  and	  thus	  Eph-­‐B4	  interaction	  with	  these	  pathways	  cannot	  be	  
assessed	  in	  this	  model	  (23,	  58).	  There	  is	  no	  site	  of	  anastomosis,	  which	  is	  a	  common	  
site	  of	  intimal	  hyperplasia	  development	  and	  restenosis	  (59).	  Vein	  rings	  in	  organ	  
culture	  cannot	  be	  infiltrated	  by	  circulating	  immune	  cells	  or	  graft	  extrinsic	  cells	  
which	  have	  been	  shown	  to	  contribute	  to	  vein	  graft	  remodeling	  (60).	  Despite	  these	  
limitations,	  saphenous	  vein	  organ	  culture	  has	  been	  employed	  in	  the	  scientific	  
literature	  since	  1990	  (61).	  The	  model	  offers	  reliable	  replication	  of	  cellular	  and	  
extracellular	  components	  seen	  in	  neointimal	  hyperplasia	  in	  vein	  grafts	  (62).	  In	  
recent	  years,	  an	  immune	  deficient	  mouse	  has	  been	  grafted	  with	  human	  arterial	  
tissue	  and	  injected	  with	  human	  immune	  cells	  as	  a	  model	  to	  study	  immune	  system	  
interaction	  with	  ischemic	  reperfusion	  injury(63).	  An	  extension	  of	  this	  model	  using	  
human	  saphenous	  vein	  and	  an	  immune	  deficient	  rat	  is	  an	  attractive	  future	  direction	  
to	  study	  Eph-­‐B4	  activation	  over	  longer	  time	  courses,	  Eph-­‐B4s	  interactions	  with	  host	  
immunity	  and	  infiltrating	  cells,	  and	  different	  drug	  delivery	  methods.	  	  
	   While	  much	  of	  the	  investigation	  of	  Eph-­‐B4	  signaling	  and	  activation	  has	  
focused	  on	  endothelial	  cells,	  it	  is	  clear	  that	  Eph-­‐B4	  is	  not	  expressed	  solely	  in	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endothelial	  cells	  and	  Eph-­‐B4	  activation	  likely	  affects	  all	  cell	  types	  in	  all	  3	  layers	  of	  
the	  vessel	  wall.	  Saphenous	  vein	  ring	  endothelial	  dependent	  relaxation	  can	  be	  tested	  
in	  vitro	  following	  treatment	  with	  a	  drug	  and	  given	  ephrin-­‐B2/Fc	  treatment	  to	  induce	  
nitric	  oxide	  release	  this	  represents	  a	  promising	  future	  direction	  for	  our	  research	  
(64).	  Also	  multiple	  techniques	  exist	  for	  smooth	  muscle	  cell	  and	  endothelial	  cell	  co-­‐
culture	  to	  investigate	  the	  interactions	  between	  cell	  types	  in	  the	  vessel	  wall	  (65).	  
Given	  the	  evidence	  that	  Eph-­‐B4	  activation	  can	  increase	  endothelial	  cell	  migration	  
and	  proliferation,	  it	  would	  be	  interesting	  to	  see	  whether	  ephrin-­‐B2/Fc	  stimulation	  
could	  attenuate	  secreted	  smooth	  muscle	  growth	  factors	  during	  endothelial	  cell	  
stress	  and	  damage.	  The	  role	  of	  extracellular	  matrix	  deposition	  and	  its	  effects	  on	  the	  
biophysical	  properties	  of	  vein	  grafts	  is	  an	  important	  aspect	  of	  vein	  graft	  adaptation	  
and	  long	  term	  patency	  in	  vivo	  (23).	  Finally	  while	  the	  current	  investigation	  has	  
shown	  that	  many	  of	  the	  findings	  in	  animal	  models	  that	  made	  Eph-­‐B4	  activation	  a	  
promising	  therapeutic	  target	  to	  reduce	  intimal	  hyperplasia	  in	  vein	  grafts	  translate	  
into	  human	  tissue,	  large	  animal	  studies	  over	  longer	  periods	  of	  time	  are	  the	  critical	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Appendix	  A:	  Schematic	  representation	  of	  bioreactor	  set	  up	  (a).	  Vein	  is	  submerged	  in	  
extraluminal	  fluid	  in	  glass	  container	  on	  right.	  It	  is	  connected	  to	  flow	  which	  is	  
regulated	  by	  programmable	  pump	  on	  left.	  Flow	  passes	  through	  compliance	  
chambers	  pre	  and	  post	  vein.	  Photo	  of	  bioreactor	  set	  up	  in	  incubator	  (b)	  Photo	  
courtesy	  of	  Lynn	  Model	  MD	  (66)	  
Roller
PUMP
Vein
